Chengdu Hyperway Pharmaceuticals (hereinafter referred to as Hyperway), an enterprise in Tianfu Life Science Park, recently announced that it has successfully obtained an angel fund of tens of millions of yuan. This round of financing was led by Huaige Capital, a domestic venture capital organization dedicated to the field of health care. It is the first time Hyperway has received capital from a professional investment organization in the field of medicine after obtaining tens of millions of angel financing in 2019.

This indicates that Hyperway's strength in research and development and development management strategy have been strongly recognized in the pharmaceutical field. The company's share value rose sharply. In the current global coronavirus outbreak when capital runs low at home and abroad, the world faces a severe financing situation, and many enterprises face the risk of capital shortage or loss, Hyperway was still favored by institutions such as Huaige Capital. This has proved the development strength of Hyperway.

 

Dr. Du Jiangbo, partner of Huaige Capital, once said, “The most attractive aspect about Hyperway is that it has a strong team. They have made the progress that most enterprises need 2-3 years to make in less than 10 months. It has unlimited development potential.”

During the coronavirus outbreak, Hyperway coordinated and closely cooperated with all sectors of the pharmaceutical industry to quickly resume work and production. While other enterprises were still in the recovery stage, Hyperway has got back on its feet and started a new round of hard work ahead of time.

 

New research and development in Hyperway

Hyperway currently runs 9 production lines to produce innovative drugs, covering the treatment of tumor, central nervous system, autoimmune system, pain, depression and so on, and has achieved encouraging results. One of the innovative drug projects has basically identified clinical candidate compounds. The project is far superior to the similar clinical compounds of several major international pharmaceutical companies in terms of in vitro inhibitory activity, selectivity, in vivo efficacy and toxicology. It is internationally advanced and is expected to have a higher safety level in clinic treatment. It has the potential to become a best-in-class drug and is expected to enter the clinical application stage.

Several candidate compounds have been found in another innovative drug project. Its preclinical data are obviously superior to the clinical drugs of major international drug companies in terms of inhibitory activity and selectivity. It is internationally advanced and is expected to have a lower clinical dose and a higher safety standard. The project is expected to quickly identify clinical candidate drugs and carry out the next round of research and development.

Recently, Xiling Lab, an enterprise in the park, signed a strategic cooperation agreement on the development of high-end generic pharmaceutical projects with BrightGene in Suzhou.

At the signing ceremony, the two sides fully affirmed the remarkable achievements made in the cooperation over the past two years and decided to further develop their respective technological and resource advantages, comprehensively enhance the depth and breadth of cooperation, accelerate the research and development and industrialization process of high-end generic drug projects, and provide patients with drugs with reliable quality and a reasonable price. At the same time, the two sides discussed upcoming cooperation projects.

Xiling Lab is a biomedical company focusing on research and development innovations and win-win cooperation. The company has a drug research and development platform with catalytic technology as the core, and focuses on the development of differentiated innovative drugs and high-end generic drugs.

BrightGene is a high-tech pharmaceutical company focusing on research and development. It is dedicated to the research, development and production of original new drugs and high-end generic drugs. With amazing development and commercialization capabilities, it provides patients with excellent products. In November 2019, it was officially listed on the Shanghai Stock Exchange's Innovation Board (stock code: 688166).

 

Signing Ceremony of Strategic Cooperation between Xiling Lab and BrightGene

● About 1 in 4 people are carriers of pathogenic genes and 1 in 20 people are carriers of various pathogenic genes. (LazarinGA et al., 2013)

● The comprehensive incidence rate of monogenic genetic diseases is about 1%. (WHO)

● Monogenic genetic diseases account for 22.2% of global birth defects. (Global Birth Defects Report, 2006)

Monogenic hereditary disease is a disease caused by a single gene defect and one of the main types of birth defects. Recessive hereditary disease is the most common type, and the parents of the patients are mostly carriers of pathogenic genes. Extended carrier screening can detect a variety of common recessive monogenic hereditary diseases at one time, help the tested to identify the risks of these diseases for their offspring, provide birth guidance and prevent the occurrence of birth defects.

Recently, Celula (China), an enterprise in the park, launched an expanded carrier screening program.

 

Product features

1. Detection of 43 kinds of monogenic hereditary diseases (including thalassemia and hereditary deafness) with high incidence in the Chinese population;

2. Accurate, efficient detection of the target gene area using multiple PCR technology;

3. Optimized trust analysis that avoids pseudogene interference;

4. Copy number detection of DMD, SMN1, CYP21A2 genes;

5. Covers the entire exon region of all transcripts of the target gene;

6. Covers hot spot mutations in intron region included in ClinVar database.

 

Disease list and related gene information:

 

Detection process:

       

The global COVID-19 outbreak poses a grim threat to life safety, and relevant research is in full swing. Pathological diagnosis, as an important step in studying the causes and pathogenesis of diseases, as well as the morphological structure, functional metabolic changes and the prognosis of diseases in the process of diseases, has provided very important theoretical and practical basis for the diagnosis, treatment and prevention of the coronavirus.

These days, the histopathology and morphological pathology diagnosis team led by two Chinese veterinary pathologists, Professor Wang Kaiyu and associate researcher Zhong Zhendong from Liai Biotechnology in the park, also conducted research on the digital scan slice of lungs diagnosed with the new coronavirus, which was obtained by a domestic research unit. Here present the findings of "Clinicopathological analysis of critically ill patients diagnosed with new coronavirus" for all of our clients in related fields for further discussion!

 

Screenshot for Pathological Section

 

Lilai Self-owned Transmission Electron Microscope Laboratory

※Contents from Chengdu Hyperway Pharmaceuticals, Xiling Lab, CELULA, and the official account of Lilai Medical Experimental Center were integrated.